In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F16%3A00011555" target="_blank" >RIV/00023736:_____/16:00011555 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1186/s12885-016-2635-0" target="_blank" >http://dx.doi.org/10.1186/s12885-016-2635-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12885-016-2635-0" target="_blank" >10.1186/s12885-016-2635-0</a>

Result language

angličtina

Original language name

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Original language description

Imatinib-resistant chronic myeloid leukemia (CML) patients receiving second-line tyrosine kinase inhibitor (TKI) therapy with dasatinib or nilotinib have a higher risk of disease relapse and progression and not infrequently BCR-ABL1 kinase domain (KD) mutations are implicated in therapeutic failure. In this setting, earlier detection of emerging BCR-ABL1 KD mutations would offer greater chances of efficacy for subsequent salvage therapy and limit the biological consequences of full BCR-ABL1 kinase reactivation. Taking advantage of an already set up and validated next-generation deep amplicon sequencing (DS) assay, we aimed to assess whether DS may allow a larger window of detection of emerging BCR-ABL1 KD mutants predicting for an impending relapse.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BMC cancer

ISSN

1471-2407

e-ISSN

—

Volume of the periodical

16

Issue of the periodical within the volume

[August]

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

"art. no. 572"

UT code for WoS article

000381216600006

EID of the result in the Scopus database

—